Positive feedback regulation of IncRNA PVT1 and HIF2α contributes to clear cell renal cell carcinoma tumorigenesis and metastasis

Ming-xiao Zhang1,5, Li-zhen Zhang1,5, Liang-min Fu1,5, Hao-hua Yao1,5, Lei Tan1,2,3, Zi-hao Feng1, Jia-ying Li1, Jun Lu1, Yi-hui Pan1, Guan-nan Shu1, Peng-ju Li1, Yi-ming Tang1, Zhuang-yao Liao1, Jin-huan Wei1, Wei Chen1, Jian-ping Guo1, Jun-hang Luo1,3,4,5 and Zhen-hua Chen1,2,3,5

© The Author(s) 2021

Long noncoding RNAs (lncRNAs) have been reported to exert important roles in tumors, including clear cell renal cell carcinoma (ccRCC). PVT1 is an important oncogenic lncRNA which has critical effects on onset and development of various cancers, however, the underlying mechanism of PVT1 functioning in ccRCC remains largely unknown. VHL deficiency-induced HIF2α accumulation is one of the major factors for ccRCC. Here, we identified the potential molecular mechanism of PVT1 in promoting ccRCC development by stabilizing HIF2α. PVT1 was significantly upregulated in ccRCC tissues and high PVT1 expression was associated with poor prognosis of ccRCC patients. Both gain-of-function and loss-of-function experiments revealed that PVT1 enhanced ccRCC cells proliferation, migration, and invasion and induced tumor angiogenesis in vitro and in vivo. Mechanistically, PVT1 interacted with HIF2α protein and enhanced its stability by protecting it from ubiquitination-dependent degradation, thereby exerting its biological significance. Meanwhile, HIF2α bound to the enhancer of PVT1 to transactivate its expression. Furthermore, HIF2α specific inhibitor could repress PVT1 expression and its oncogenic functions. Therefore, our study demonstrates that the PVT1/ HIF2α positive feedback loop involves in tumorigenesis and progression of ccRCC, which may be exploited for anticancer therapy.

Oncogene (2021) 40:5639–5650; https://doi.org/10.1038/s41388-021-01971-7

INTRODUCTION

Renal cell carcinoma (RCC) is a common malignancy of the urinary system, comprising ~3% of all cancers. The morbidity of RCC is growing by 2% per year during the past two decades globally [1]. Clear cell RCC (ccRCC) is the most common pathological type of RCC, accounting for 75–80% of all RCC patients. About 20–30% of ccRCC patients are diagnosed at an advanced stage with distant organ metastasis and exhibit poor prognosis due to ineffectiveness of various treatments [2, 3]. For non-metastatic ccRCC, although early diagnosis and aggressive surgery significantly improve outcomes, the recurrence rate is still up to 20–40% after partial or radical nephrectomy [4]. Therefore, it is highly worthwhile to explore the pathogenesis of ccRCC for better treatment strategies.

Genetically, ccRCC is associated with inactivation of von Hippel-Lindau (VHL) tumor suppressor gene caused by the chromatin deletion together with its frequent mutation and promoter methylation [5]. pVHL, the protein encoded by VHL, recruits several proteins to form the VCB (VHL-elongin C-elongin B)-Cul2 E3 ubiquitin ligase and serves as the subunit to specifically recognize substrates, such as hypoxia-inducible factor α (HIFα, including HIF1α and HIF2α). Importantly, only the hydroxylated HIFα could be targeted by pVHL for ubiquitination and degradation under normoxic conditions [6, 7]. Conceivably, either inactivation of VHL or hypoxic conditions could abolish the interaction of pVHL and HIFα, leading to excessive accumulation of HIFα and subsequent transcriptional activation of hypoxia-responsive genes, such as VEGF, PDGF, and Cyclin D1 [8]. More importantly, although both HIF1α and HIF2α could be regulated by pVHL in a hydroxylation-dependent manner, HIF2α, but not HIF1α, plays a critical oncoprotein role in ccRCC tumorigenesis [9–12]. To this end, small inhibitors targeting HIF2α, but not HIF1α, have been developed to repress ccRCC growth and already underwent clinical trial waiting for FDA approval for ccRCC therapies [13–15]. However, except pVHL, other upstream regulation for HIF2α is not well defined.

Long non-coding RNAs (lncRNAs), which are defined as non-coding RNA transcripts longer than 200 nucleotides, play important roles in many diseases, including cancer [16]. LncRNAs are governing diverse cellular processes, ranging from cis- to trans-regulation of gene expression and from epigenetic modulation in nucleus to post-transcriptional regulation in cytoplasm [17, 18]. Among all dysregulated lncRNAs in cancers, PVT1 is particularly compelling because emerging studies have revealed...
that PVT1 fulfills significant oncogenic effects in the onset and progression of various cancers, including ccRCC [19–28]. Although several regulatory mechanisms of PVT1 have been reported, such as interacting with Myc and modulating the function of microRNAs and regulation of different proteins [21, 23, 29], the underlying molecular mechanism remains to be further investigated, especially in the ccRCC setting.

Here, we identify that PVT1 plays a vital role in ccRCC growth and metastasis, and high PVT1 expression is correlated with poor overall survival (OS) and progression-free survival (PFS) of ccRCC. Mechanistically, PVT1 interacts with HIF2α and impedes ubiquitin-dependent HIF2α degradation. Moreover, PVT1 is a direct transcriptional target of HIF2α. These findings together suggest that the positive feedback loop between PVT1 and HIF2α may promote tumor development and serve as a promising therapeutic target of ccRCC.

RESULTS

PVT1 is upregulated in ccRCC tissues and high PVT1 level associates with poor prognosis

The biological significance of PVT1 was first explored using human tumor tissues and the matched adjacent normal tissues. qPCR analysis of our ccRCC cohort revealed that PVT1 expression was significantly elevated in ccRCC tissues (Fig. 1A), which was further confirmed by analysis of the transcriptome data from the TCGA KIRC cohort (Supplementary Fig. S1A). Using the median level of PVT1 as the cut-off value, we stratified the ccRCC patients into low- and high-PVT1 expression groups. The Kaplan-Meier survival analysis demonstrated that high-PVT1 expression group showed greater tumor size, increased lymph node metastasis, and distant metastasis compared with low-PVT1 expression group (Supplementary Table 1). Moreover, high PVT1 expression was also correlated with poor overall survival (OS) and progression-free survival (PFS) in our ccRCC cohort (Fig. 1B). Similar results were also observed in the analysis of TCGA KIRC cohort (Supplementary Fig. S1B). These results together suggest that PVT1 may play an important role in ccRCC tumorigenesis and progression, and serve as a valuable prognostic marker in ccRCC.

PVT1 promotes the malignant phenotypes of ccRCC cells in vitro

We next explored the potential role of PVT1 in ccRCC development. To this end, we initially measured the expression of PVT1 in immortalized proximal tubule epithelial cells (HK-2) and a panel of ccRCC cell lines (769-P, 786-O, UMRC6, ACHN, RCCJF, A498, Caki-1). Consistent with our clinical observation, PVT1 was upregulated in ccRCC cell lines compared with HK-2 cells (Fig. 1C). Several studies have reported the facilitating effects on cell proliferation, migration and invasion of PVT1 in ccRCC [25–28], thus we conducted gain and loss of function experiments to validate these oncogenic functions. Silencing PVT1 in 786-O and A498 cells or overexpressing PVT1 in 769-P cells (Fig. 1D), dramatically suppressed or promoted cell proliferation and colony formation, respectively (Supplementary Fig. S1C-F). We also conducted wound-healing assays and found that knockdown of PVT1 markedly impaired the mobility of 786-O and A498 cells, whereas overexpression of PVT1 improved the mobility of 769-P cells (Fig. 1E, F). In addition, transwell migration and matrigel invasion assays were further performed and validated that knockdown of PVT1 significantly inhibited migration and invasion of 786-O and A498 cells, and reverse results were observed in 769-P cells with ectopic expression of PVT1 (Supplementary Fig. S1G-J). More importantly, HUVECs, which were incubated with conditioned medium collected from PVT1-knockdown 786-O and A498 cells, formed fewer capillary tubes compared with control groups (Fig. 1G). In contrast, conditioned medium collected from PVT1-overexpression 769-P cells remarkably improved the tube formation ability of HUVECs (Fig. 1H). These findings indicate that PVT1 may exert more important roles in the progression of ccRCC by promoting tumor angiogenesis.

PVT1 promotes ccRCC proliferation, angiogenesis and metastasis in vivo

To investigate the potential role of PVT1 in vivo, a renal orthotopic mouse model was employed. PVT1-silencing 786-O cells or counterpart control 786-O cells were injected into the renal subcapsule of BALB/c nude mice. As shown, knockdown of PVT1 dramatically inhibited the growth rate of xenograft in vivo (Fig. 2A, B). Consistently, PVT1-silencing tumors displayed a lower microvessel density (MVD) compared with those of control group (Fig. 2C). In addition, tail-vein injection mouse model was employed, and the results showed that PVT1 depletion dramatically compromised the ability of 786-O cells in promoting lung metastases compared with the control group (Fig. 2D, E). Taken together, our findings indicate that PVT1 may significantly facilitate ccRCC proliferation, angiogenesis and metastasis in vivo.

PVT1 binds and stabilizes HIF2α in ccRCC cells

To point out the underlying molecular mechanism of PVT1 in promoting ccRCC angiogenesis, invasion and migration, we initially performed the RNA-FISH assays and revealed that PVT1 was predominantly located in the cytoplasm rather than the nucleus, indicating that PVT1 may exert its oncogenic effect in the cytoplasm (Fig. 3A). Generally, lncRNAs are prone to function by binding and modulating proteins. Thus, we performed RNA pull-down assays to indentify PVT1-associated proteins (Fig. 3B left panel). Mass spectrometry analysis identified HIF2α as one of the top binding proteins for PVT1 (Supplementary Table 2 and Supplementary Table 3), which was further validated by western blot in independent RNA pull-down assays (Fig. 3B right panel). On the other hand, RIP assays were performed and showed that PVT1 was remarkably enriched in HIF2α-immunoprecipitated RNAs (Fig. 3C). Altogether, these findings indicate that PVT1 is associated with HIF2α in ccRCC cells.

To further dissect the regulatory effect of PVT1 on HIF2α, we measured HIF2α expression in VHL-deficient ccRCC cells (786-O and A498) at both RNA and protein levels. The results showed that knockdown of PVT1 did not affect the mRNA level of HIF2α (Fig. 3D), but significantly down-regulated its protein levels in both 786-O and A498 cells (Fig. 3E). In addition, IHC staining of xenografts deriving from PVT1-deficient 786-O cells also displayed lower HIF2α abundance compared with controls (Fig. 3F). Consistently, the expression of well-known HIF2α downstream targets, such as E2F1, Cyclin D1 and VEGF [30–32], were reduced upon PVT1 depletion (Fig. 3G). In addition, PVT1 knockdown significantly decreased the protein production of VEGF in the supernatant derived from 786-O and A498 cells (Fig. 3H).

Since around 70% ccRCC display VHL genetic mutations or deletion, both HIF1α and HIF2α display a relative high level in these tissues. Here we demonstrate that PVT1 could stabilize HIF2α possibly in a post-transcriptional level, thus we tend to further investigate the underlying mechanism. We found that silencing PVT1 in VHL-deficient ccRCC cells could dramatically decreased the stability of HIF2α protein (Fig. 4A), coupled with notably improving HIF2α polyubiquitination (Fig. 4B). Furthermore, PVT1 silencing-mediated down-regulation of HIF2α could be rescued by treatment with proteasome inhibitor MG132 (Fig. 4C). These results together suggest that PVT1 may associate with HIF2α to protect it from ubiquitination-mediated degradation in a pVHL-independent manner.

PVT1 augments tumor growth and metastasis largely by promoting HIF2α pathway

To test whether PVT1 plays its oncogenic role via HIF2α, we overexpressed HIF2α in PVT1-silencing 786-O and A498 cells (Fig. 5A; Supplementary Fig. 52A). As shown, ectopic expression of
High PVT1 expression in ccRCC tissues and cells associates with poor clinical outcomes and malignant phenotypes respectively. A Relative PVT1 expression level was assessed by qPCR in 140 pairs of ccRCC and the matched adjacent normal tissues. B Survival analysis showed that high PVT1 expression was correlated with poor OS and PFS in our ccRCC cohort. C Expression levels of PVT1 in immortalized proximal tubule epithelial cells (HK-2) and different ccRCC cell lines were detected. D PVT1 was silenced in 786-O and A498 cells by two different shRNA (left panel) and overexpressed in 769-P cells (right panel). E, F Wound-healing assays showed that knockdown of PVT1 markedly impaired mobility of ccRCC cells, whereas overexpression of PVT1 enhanced it. Representative images and results of quantitative analysis were shown. Wound areas were calculated by Image J. G, H The tube formation of HUVECs was repressed when cultured in conditioned medium from PVT1-silencing cells, but promoted when cultured in conditioned medium from PVT1-overexpression cells. **p < 0.01, ***p < 0.001.
HIF2α largely abrogated PVT1 silencing-induced inhibition of 786-O and A498 cells proliferation as well as HUVECs tube formation (Fig. 5B, C; Supplementary Fig. S2B, C). Moreover, wound-healing assays, transwell migration and matrigel invasion assays also showed that HIF2α overexpression attenuated the inhibition effects of PVT1 knockdown on ccRCC cells migration and invasion (Fig. 5D, E; Supplementary Fig. S2D, E). Similarly, depletion of HIF2α impaired the promotive effects of PVT1 overexpression on proliferation, migration and invasion of ccRCC cells along with tube formation of HUVECs (Fig. 5F-J). Taken together, our results...
uncover that PVT1 facilitates ccRCC malignant phenotypes mainly via activating HIF2α pathway.

**HIF2α enhances PVT1 transcription to form a positive feedback regulatory loop**

It is previously reported that HIF could directly bind to an enhancer located between the MYC and PVT1 gene locus and enhance transcription of these genes [33]. Thus, a hypoxia response element (HRE) has been identified in the PVT1 enhancer, which locates 14 kb upstream of PVT1 (Fig. 6A). In keeping with this finding, we found that the RNA levels of PVT1 were significantly reduced in HIF2α-depleted 786-O cells while increased in HIF2α-overexpressing 769-P cells (Fig. 6B). To further validate the direct regulation of HIF2α on PVT1, ChIP assays were performed and revealed that HIF2α was remarkably enriched within the HRE region of PVT1 (Fig. 6C). On the other hand, we observed that ectopic expression of HIF2α increased the activity of luciferase reporter containing wild-type but not mutant PVT1 HRE (Fig. 6D), indicating that HIF2α positively regulates PVT1 expression, which forms a positive feedback loop, to further enhance HIF2α accumulation and promote tumorigenesis.

**HIF2α inhibitor blocks the PVT1-HIF2α positive feedback loop and its oncogenic roles in ccRCC**

As a predominant target of ccRCC, HIF2α has drawn more attention as a result of VHL deficiency, and its inhibitors recently have been successfully developed and undergone clinical trial [13–15]. With the evidence that HIF2α transcriptionally regulated PVT1, HIF2α specific inhibitor PT2385 may thus largely compromise PVT1 expression. As expected, in vivo xenograft experiments showed that PT2385 significantly inhibited tumor growth coupled with decreased PVT1 expression (Fig. 6E, F). On the other hand, consistent with our previous finding, the oncogenic roles of PVT1 could be markedly abrogated by PT2385 treatment in vitro (Fig. 6G–I), indicating that PVT1 performs its oncogenic roles at least partially via activating HIF2α pathway. These findings together suggest that HIF2α inhibitor is efficient for combating high-PVT1 or -HIF2α expression ccRCC by blocking the positive feedback regulatory loop between PVT1 and HIF2α (Fig. 6).

**DISCUSSION**

Growing evidence has shown that ubiquitin-dependent protein degradation plays critical roles in post-transcriptional regulation of HIFα. Under normoxia conditions, HIFα is hydroxylated on specific proline residues by prolyl hydroxylases (PHDs) and in turn undergoes proteasomal degradation via a pVHL-dependent pathway [34]. Beside pVHL, other E3 ligases have also been reported to be responsible for the regulation of HIFα via an oxygen-independent pathway. For example, Heat shock protein 90 (Hsp90) was reported to physically interact with HIF1α and enhance its stabilization;[35, 36] receptor of activated protein C kinase (RACK1) competes with Hsp90 for binding to HIF1α and recruits the elongin B & C E3 ligase complex to target HIF1α for proteasomal degradation [37]. Similarly, The E3 ligase culin 5 also mediates HIF1α degradation in an Hsp90-mediated and oxygen-independent manner [38]. Nevertheless, there is no clear evidence that E3 ligase other than pVHL involves in the degradation of HIF2α. Here we revealed that PVT1 protected HIF2α from polyubiquitination and subsequent proteasomal degradation in VHL-deficient renal cancer cells. Thus, exploration of novel E3 ligase interacting with HIF2α and mediating it undergo ubiquitination-proteasome degradation pathway would be an interesting question that should be further investigated in future.

Prior studies have demonstrated that PVT1 is an important oncogene and plays critical roles in onset and development of various cancers [39]. Here we found that PVT1 was dramatically upregulated in ccRCC tissues and predicted shorter survival time, which were consistent with previous studies about the clinical significance of PVT1 in ccRCC [25, 26]. Meanwhile, several studies found that PVT1 exerts oncogenic effects in ccRCC by promoting proliferation, migration and invasion of ccRCC cells [25–27]. In our study, in vitro and in vivo experiments both verified that PVT1 significantly promoted malignant biological behavior of ccRCC cells, especially tumor angiogenesis. PVT1 exerts various biological effects via interacting with different functional proteins, such as increasing the stability of NOP2 [40], or binding with transcriptional factor FOXM1 and STAT3 [19, 23]. Here we identified that PVT1 exerted its angiogenesis role by binding and stabilizing HIF2α in ccRCC cells. More interestingly, PVT1 protects HIF2α from ubiquitination and subsequent degradation in a pVHL-independent manner. This finding further provides evidence that other E3 ligase(s) except pVHL is present to regulate HIF2α stability, thus PVT1 may bind HIF2α to attenuate its binding with E3 ubiquitin ligase or enhance its binding with according deubiquitinase, which is worth to be further investigated.

Although HIF1α and HIF2α undergo a similar regulation by the PHD-mediated hydroxylation and pVHL-mediated ubiquitination, these two proteins also display a distinct function in ccRCC. Among which HIF2α has been considered as an oncogene to promote ccRCC tumorigenesis, while HIF1α exhibits a tumor suppressor role [9–12]. Although PVT1 has been shown to regulate HIF1α transcriptionally by binding with KAT2A and play oncogenic roles in cancers [41], we demonstrated that PVT1 could bind HIF2α and stabilize HIF2α protein, thus promote tumorigenesis and angiogenesis. As a result, the oncogenic functions of PVT1 in ccRCC are mainly mediated by HIF2α but not HIF1α. Thus, HIF2α specific inhibitors could dramatically repress PVT1 oncogenic functions in ccRCC. Reciprocally, HIF2α can increase PVT1 expression by occupying the HRE within the enhancer of PVT1 and form a positive feedback loop, thus the sustained HIF2α will mediate PVT1 oncogenic functions for ccRCC tumorigenesis.

**MATERIALS AND METHODS**

**Cell culture and clinical samples**

HK-2, 769-P, 786-O, UMRC6, ACHN, RCCJF, A498, CAKI-1 and human umbilical vein endothelial cell (HUVEC) were purchased from the Chinese Academy of Science. HK2, UMRC6, ACHN, A498 and HUVEC were cultured...
in DMEM medium supplemented with 10% fetal bovine serum (FBS). 769-P, 786-O and RCCJF were grown in RPMI-1640 medium with 10% FBS. CAKI-1 was maintained in McCoy’s 5A medium with 10% FBS. All cells were cultured in a humidified incubator with 5% CO2 at 37 °C. All cell lines were authenticated by the short tandem repeat DNA profiling test and tested negative for mycoplasma contamination. A total of 140 paired ccRCC samples and matched adjacent normal tissues (ANTs) were collected from Sun Yat-sen University Cancer Center (Guangzhou, China), from December 2007 to December 2018. The clinicopathological information of all 140 patients is provided in Supplementary Table 1. Samples used in this study
were approved by Ethical Committee of Sun Yat-sen University Cancer Center (Guangzhou, China). The informed consent of each patient was obtained.

**Plasmid construct, siRNA interference and shRNA transfection**

Plasmids encoding HIF2α and ubiquitin were gifts from Professor Jianping Guo (The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China). siRNA targeting HIF2α and scrambled siRNA were synthesized by Ribobio (Guangzhou, China). Short hairpin RNA (shRNA) directed against PVT1 was synthesized and cloned into GV367 vector (GeneChem, Shanghai, China). For PVT1 overexpression plasmid, cDNA of PVT1 was cloned into pcDNA3.1 vector (Invitrogen, CA, USA); anti-VEGF antibody (Catalog number: 19003-1-AP, 1:1000) was purchased from Cell signaling Technology (MA, USA); anti-E2F1 antibody (Catalog number: ab199, 1:1000), anti-cyclin D1 antibody (Catalog number: 3742, 1:1000), anti-Cyclin D1 antibody (Catalog number: 55506, 1:1000) and anti-Beta-actin antibody (Catalog number: 4790, 1:1000) were all purchased from abcam (Cambridge, UK); anti-VEGF antibody (Catalog number: 19003-1-AP, 1:1000) was purchased from Proteintech (Wuhan, China). Then membranes were incubated with HRP-conjugated anti-rabbit IgG at room temperature for 1 h and signal detection was visualized using a western blot substrate kit (Tanon, Shanghai, China).

**MTT and colony formation assays**

For MTT assays, a total of 1500 cells were seeded per well in a 96-well plate. MTT assay reagent (Beyotime, Shanghai, China) was added to each well and incubated for 2 h at 37 °C. Newly formed mitochondrial formazan crystals were dissolved by 100 µL DMSO and the absorbance at 490 nm of each well was read on a spectrophotometer. For colony formation assays, a total of 1000 cells were seeded per well in a 6-well plate. After cultured for 2 weeks, the colonies were fixed with 4% parafomaldehyde for 20 min at room temperature and then stained with 0.1% crystal violet. The number of colonies (>50 cells) was counted.

**Tube formation assay**

Each well of a 96-well plate was coated with 50 µL matrigel (Corning, NY, USA), and incubated for 30 min at 37 °C. Then HUVECs (20,000 per well) were seeded in the matrigel pre-coated wells and cultured with conditioned culture medium at 37 °C for 6 h. The formation of capillary-like structures was monitored under a light microscope, and counted by Image J software.

**Wound-healing, transwell migration and matrigel invasion assays**

For wound-healing assays, the confluent monolayer was scratched using a 200 µL pipette tip. The movement of ccRCC cells was determined in this artificial scratch by monitoring the speed of wound closure. Transwell migration assays and matrigel invasion assays were performed using a 24-well transwell chamber (Corning, NY, USA) with or without matrigel. The movement of ccRCC cells was determined according to our experience as well as literature reporting in vivo. Orthotopic xenograft tumor model, 4-week-old male BALB/c nude mice were used. 18 nude mice were randomly allocated into 3 groups, and anesthetized with 1% pentobarbital (50 mg/kg body weight) by intraperitoneal injection. PVT1-silencing 786-O-luc cells or counterpart control 786-O-luc cells (1×10^6) were injected into the right renal subcapsule orthotopically. 6 weeks after injection, mice were sacrificed and kidneys with xenograft tumors were removed for further analysis. Orthotopic xenograft weight was estimated by subtracting the weight of the contralateral kidney from the weight of kidney with xenograft tumor. For drug treatment assays, HIF2α antagonism, PT2385 (AbMole, TX, USA) was suspended in saline containing 2% demethyl sulfoxide (DMSO), 2.5% Tween 80 and 0.5% sodium carboxymethyl cellulose. 12 nude mice bearing 786-O-luc cells orthotopically were randomly divided into 2 groups. 2 weeks after injection of 786-O cells, nude mice of 2 groups were orally treated with vehicle or PT2385 (10 mg/kg body weight) twice daily respectively until the endpoint. For tail-vein injection lung metastasis assays, 18 nude mice were randomly allocated into 3 groups. PVT1-silencing 786-O-luc cells or counterpart control 786-O-luc cells (1×10^7) were injected intravenously into each mouse through the tail vein. The experimental mice were sacrificed after 6 weeks. The lung of each mouse was removed and the pulmonary metastatic nodules were counted. To detect tumor growth and metastasis, nude mice bearing 786-O-luc cells were injected with D-Luciferin (150 mg/kg body weight) intraperitoneally. Bioluminescence signals were collected and analyzed by IVIS Spectrum.

No sample size calculations were performed. Sample size was determined according to our experience as well as literature reporting in terms of specific experiment. Randomization method was used to determine how animals were allocated to different groups. To achieve randomization, all animals were numbered by body weight, then, random number table was used to allocate animals to experimental groups. During the study, no data was excluded from the experiments, and no blinding was done.
Fig. 4  PVT1 protects HIF2α from ubiquitination-mediated degradation. A PVT1 knockdown decreased the stability of HIF2α protein. 786-O and A498 cells stably expressing control shRNA or PVT1 shRNA were incubated with cycloheximide (CHX, 100 μg/ml) for the indicated interval, following by western blot (left panel). The quantified level of HIF2α protein was measured by Image J. B Ubiquitination assays showed that PVT1 knockdown increased the polyubiquitination level of HIF2α. Cells were transfected with the indicated plasmids for 48 h, and then His-Ub conjugated proteins were pulled down with Ni-NTA agarose beads. The anti-HIF2α antibody was used to detect the polyubiquitination level of HIF2α. C The proteasome inhibitor MG132 rescued PVT1 silencing-induced HIF2α reduction. Cells expressing control shRNA or PVT1 shRNA were incubated with MG132 (20 μM) for 4 h before western blot. **P < 0.01, ***P < 0.001.
Fig. 5  PVT1 accelerates tumor growth and metastasis mainly via promoting HIF2α pathway. A Overexpressing HIF2α rescued the PVT1 silencing-induced down-regulation of HIF2α. Overexpressing HIF2α abrogated PVT1 silencing-induced inhibition of proliferation of ccRCC cells (B), tube formation of HUVECs (C), migration and invasion of ccRCC cells (D–E). F Silencing HIF2α inhibited PVT1 overexpression-mediated up-regulation of HIF2α. Silencing HIF2α abrogated the roles of PVT1 overexpression in promoting proliferation of ccRCC cells (G), tube formation of HUVECs (H), migration and invasion of ccRCC cells (I–J). **P < 0.01, ***P < 0.001.
**Immunohistochemistry (IHC) staining**

Paraffin sections of xenograft tumors were baked in an oven at 65 °C for 1 h. Then, the paraffin sections were deparaffinized in xylene and rehydrated by graded ethanol. After performing antigen retrieval with EDTA antigen retrieval solution, the sections were treated with 3% H$_2$O$_2$ to block the endogenous peroxidase activity, followed by incubating in blocking buffer (5% bovine serum albumin). Anti-HIF2α antibody (Abcam, catalog number: ab199, 1:100) and anti-CD34 antibody (Abcam, catalog number: ab81289, 1:2500) were added on the sections and incubated in a humidified chamber at 4 °C overnight. Then, the sections were incubated in horseradish peroxidase conjugated goat anti-rabbit IgG (ZSGB-BIO, Beijing, China) for 20 min at room temperature. DAB substrate solution
In vitro ubiquitination assay

786-O and A498 cells were transfected with plasmids expressing HIF2α and His-tagged ubiquitin (His-ub). 48 h later, cells were incubated with 20 μM MG132 for 4 h before harvesting. Then, the culture medium was aspirated and 1 ml of PBS was added. Cells were scraped off with a cell scraper and centrifuged at 2500 rpm for 6 min. The pelleted cells were resuspended by buffer A (6 M Guanidine-HCl, 0.1 M Na2HPO4, 0.1 M NaH2PO4, 10 mM imidazole, pH 8.0). After being sonicated and blotted as described above, proteins pulled down by Ni-NTA agarose beads were incubated with 20 mM imidazole, pH 6.8), and twice with buffer TI. The His-Ub conjugated proteins were washed by centrifugation, the cell lysates were incubated with 50 µl Ni-NTA agarose beads for 3 h at room temperature. The pull-down products were washed by buffer A, once with 1:3 buffer A/buffer TI (25 mM Tris-HCl, pH 6.8), and twice with buffer TI. The immunoprecipitated DNA was purified and then analyzed by qPCR. The primers used to analyze the enriched DNA are listed in Supplementary Table 4.

For luciferase reporter assays, the PVT1 enhancer with canonical hypoxia response element (HRE) and a mutated version of the HRE were inserted into GV148 vector (GeneChem, Shanghai, China) respectively. ccRCC cells were transfected with HIF2α-expressing plasmid and GV148-based reporter plasmid as described. Meanwhile, COV45 Renilla luciferase plasmid (GeneChem, Shanghai, China) was co-transfected as internal control. 48 h after transfection, the cells were lysed and assayed via dual-luciferase reporter assay kit (Promega, WI, USA). Luciferase activity was normalized to the Renilla.

All experiments were replicated for three parallel experiments.

Statistical analysis

All statistical analyses were performed using R (version 3.6.3). Two-tailed student’s t-test was used in the intergroup comparison. The association between clinicopathological parameters and the expression level of PVT1 was analyzed using chi-square test. We calculated the coefficient of variation and comparisons between the groups were performed. P value < 0.05 was considered statistically significant.

REFERENCES

1. Lugnborg B, Albigeis L, Abu-Ghamem Y, Benjalsoh K, Dabestani S, Fernández-Pello S, et al. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol. 2019;75:799–810.

2. Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs. 2007;67:1257–64.

3. Oudard S, George D, Medioni J, Motzer R Treatment options in renal cell carcinoma: past, present and future. Ann Oncol. 2007;suppl 10:s25–31.

4. Frank I, Blute M, Cheville J, Lohse C, Weaver A, Leibovich B, et al. A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma. J Urol. 2003;170:225–32.

5. Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 2009;76:939–45.

6. Ohh M, Park C, Ivan M, Hoffman M, Kim T, Huang L, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000;19:4298–30.

7. Rankin E, Giaccia A. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008;15:678–85.

8. Gordan JD, Lal P, Dondeti VR, Leteoro R, Parekh KN, Oquendo CE, et al. Hypoxia effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008;13:580–93.

9. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretto S, et al. Genetic and functional studies implicate HIF2α as a 14q kidney cancer suppressor gene. Cancer Discov. 2011;1:1222–35.

10. Turajlic S, Xu H, Litchfield K, Rowan A, Chambers T, Lopez JL, et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell. 2018;173:581–594.e512.

11. Chen W, Hill H, Christie A, Kim MS, Holloman E, Pavia-Jimenez A, et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016;539:112–7.
14. Wallace EM, Rizzi JP, Han G, Wehn PM, Cao Z, Du X, et al. A small-molecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma. Cancer Res. 2016;76:5491–5500.

15. Courtney KD, Infante JR, Lam ET, Figlin RA, Rini BI, Brugarolas J, et al. Phase I dose-escalation trial of PTZ385, a first-in-class hypoxia-inducible factor-2α antagonist in patients with previously treated advanced clear cell renal cell carcinoma. J Clin Oncol. 2018;36:867–74.

16. Sun M, Kraus WL. From discovery to function: the expanding roles of long noncoding RNAs in physiology and disease. Endocr Rev. 2015;36:25–64.

17. Mercer T, Dinger M, Mattick J. Long non-coding RNAs: insights into functions. Nat Rev Genet. 2009;10:155–9.

18. Ulltsey I, Bartel D. lncRNAs: genomics, evolution, and mechanisms. Cell. 2013;154:26–46.

19. Xu MD, Wang Y, Weng W, Wei P, Qi P, Zhang Q, et al. A positive feedback loop of IncRNA-PVT1 and FOXM1 facilitates gastric cancer growth and invasion. Clin Cancer Res. 2017;23:2071–80.

20. Xu Y, Li Y, Jin J, Han G, Sun C, Pizzi M, et al. LncRNA PVT1 up-regulation is a poor prognosticator and serves as a therapeutic target in esophageal adenocarcinoma. Mol Cancer. 2019;18:141.

21. Zhao L, Hong S, Chen Z, Chen B, Zhou M. LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448. J Cell Physiol. 2018;233:4044–55.

22. Yu X, Zhao J, He Y. Long non-coding RNA PVT1 functions as an oncogene in human colon cancer through miR-30d-5p/RUNX2 axis. J Buon. 2018;23:48–54.

23. Zhao J, Du P, Cui P, Qin Y, Hu C, Wu J, et al. LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer. Oncogene. 2018;37:4094–109.

24. Wang H, Li Z, Xu Z, Chen Y, Lu Z, Shen D, et al. The prognostic value of miRNA-18a-5p in clear cell renal cell carcinoma and its function via the miRNA-18a-5p/ HIF1A/PVT1 pathway. J Cancer. 2020;11:2737–48.

25. Ren Y, Huang W, Weng G, Cui P, Liang H, Li Y. LncRNA PVT1 promotes proliferation, invasion and epithelial-mesenchymal transition of renal cell carcinoma cells through downregulation of miR-16-5p. Oncog Targets Ther. 2019;12:2563–75.

26. Wu Q, Yang F, Yang Z, Fang Z, Fu W, Chen W, et al. Long noncoding RNA PVT1 inhibits renal cancer cell apoptosis by up-regulating Mcl-1. Oncotarget. 2017;8:101865–75.

27. Yang T, Zhou H, Liu P, Yan L, Yao W, Chen K, et al. IncRNA PVT1 and its splicing variant function as competing endogenous RNA to regulate clear cell renal cell carcinoma progression. Oncotarget. 2017;8:53653–67.

28. Li W, Zheng Z, Chen H, Cai Y, Xie W. Knockdown of long non-coding RNA PVT1 induces apoptosis and cell cycle arrest in clear cell renal cell carcinoma through the epidermal growth factor receptor pathway. Oncol Lett. 2018;15:7855–63.

29. Tseng Y, Moriarity B, Gong W, Akiyama R, Tiwari A, Kawakami H, et al. PVT1 dependence in cancer with MYC copy-number increase. Nature. 2014;512:82–86.

30. Baba M, Hirai S, Yamada-Okabe H, Hamada K, Tabuchi H, Kobayashi K, et al. Loss of p53 and RACK1 antagonize HIF2α in preclinical models of renal cell carcinoma. Cancer Res. 2016;76:5491–5500.

31. Ehrlich ES, Wang T, Luo K, Xiao Z, Niewiadomska AM, Martinez T, et al. Regulation of Hsp90 client proteins by a Cullin5-RING E3 ubiquitin ligase. Proc Natl Acad Sci USA. 2009;106:20330–5.

32. Li MY, Tang XH, Fu Y, Wang TJ, Zhu JM. Regulatory mechanisms and clinical applications of the long non-coding RNA PVT1 in cancer treatment. Front Oncol. 2019;9:787.

33. Wang F, Yuan JH, Wang SB, Yang F, Yuan SX, Ye C, et al. Oncofetal long non-coding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology. 2014;60:1278–90.

34. Wang Y, Chen W, Lian J, Zhang H, Yu B, Zhang M, et al. The IncRNA PVT1 regulates nasopharyngeal carcinoma cell proliferation via activating the KAT2A acetyltransferase and stabilizing HIF-1α. Cell Death Differ. 2020;27:695–710.

ACKNOWLEDGEMENTS
We thank the TCGA for their efforts and providing data.

AUTHOR CONTRIBUTIONS
ZHC, JHL, and JPG designed the project. MXZ, LZZ, LMF, HHY, LT, ZHF, JYL, JL, YHP, GNS, PJL, and ZYL performed the experiments. JHW and YMT revised the manuscript. All authors read and approved the final manuscript.

FUNDING
This work was supported by the National Natural Science Foundation of China (No.81902576, No.81725016, No. 81872094 and No. 82002684), the Natural Science Foundation of Guangdong Province, China (2017B020227004), 2017A030313358, 2018A030310327), the Medical Scientific Research Foundation of Guangdong Province, China (A2018051), Guangdong Basic and Applied Basic Research Foundation (2020A1515111077), and China Postdoctoral Science Foundation Funded Project (No. 236464).

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41388-021-01971-7.

Correspondence and requests for materials should be addressed to J.-p.G., J.-h.L. or Z.-h.C.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.